+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The World Liquid Biopsy Market 2021

  • ID: 5521308
  • Report
  • January 2022
  • Region: Global
  • 228 Pages
  • Kalorama Information

 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


This report, The World Liquid Biopsy Market, 2021, contains up-to-date information and useful data points for business planning:

  • Research vs. Clinical Liquid Biopsy
  • The Market for Liquid Biopsy by Region
  • The Market for Liquid Biopsy Market by Type of Analyte
  • The Market for CTC-based Liquid Biopsy
  • The Market for ctDNA-based Liquid Biopsy
  • The Market for EV and Exosome-based Liquid Biopsy
  • The Market for Multi-Analyte-based Liquid Biopsy
  • The Market for Other Liquid Biopsy
  • Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
  • Selected ctDNA-based Liquid Biopsy Tests in Development
  • Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
  • Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.


Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

  • Early detection and diagnosis/screening
  • Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
  • Therapy personalization and monitoring - by molecular characterization of a patient’s disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
  • Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
  • Prognosis of disease

Table of Contents

CHAPTER 1: EXECUTIVE SUMMARY
INTRODUCTION
LIQUID BIOPSY TECHNOLOGIES
INDUSTRY STRUCTURE
LIQUID BIOPSY MARKET REVENUES AND FORECAST
  • Figure 1-1: Global Liquid Biopsy Market by Geographic Region, 2021 (%)
  • Table 1-1: Global Liquid Biopsy Market Forecast, by Region ($ millions), 2021-2026
  • Figure 1-2: Global Liquid Biopsy Market Forecast by Region $ millions), 2021-2026


CHAPTER 2: LIQUID BIOPSY TECHNOLOGIES
INTRODUCTION
  • Table 2-1: Comparison of Tissue and Liquid Biopsy


CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES
  • Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies


CHAPTER 3: CIRCULATING TUMOR DNA (CTDNA) LIQUID BIOPSY
INTRODUCTION
ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
CURRENT CTDNA-BASED LIQUID BIOPSY TESTS
  • Table 3-1: Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2021


Biocartis
Biocept
Biodesix
CellMax Life
Circulogene
Diacarta
Epigenomics
Foundation Medicine (Roche)
Guardant Health
Inivata (Neogenomics)
LungLife AI
Myriad Genetics
NeoGenomics
OncoDNA
Personal Genomic Diagnostics
QIAGEN
Resolution Biosciences
Roche Diagnostics
Sysmex-Inostics
Tempus
CTDNA-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
  • Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development


Exact Sciences
Freenome
GRAIL
Neogenomics


CHAPTER 4: CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY
INTRODUCTION
CHALLENGES IN THE DEVELOPMENT OF CTC-BASED LIQUID BIOPSY TESTS
CTC-BASED LIQUID BIOPSY TESTS
  • Table 4-1: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021


Adaptive Biotechnologies
Biocept
CellMax Life
Epic Sciences
GILUPI
LungLife AI
Menarini-Silicon Biosystems
QIAGEN
CTC-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
  • Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2021


ANGLE
Epic Sciences
Liquid Biotech USA


CHAPTER 5: EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY
INTRODUCTION
LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES/OTHER ANALYTES
  • Table 5-1: Selected Market-Available Liquid Biopsy Tests based on Extracellular Vesicles/Other Analytes, 2021


Aspira Women’s Health (formerly Vermillion)
Biodesix
Exosome Diagnostics
Hologic
MDxHealth
EXTRACELLULAR VESICLE/OTHER ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
  • Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2021


Circulogene
OncoCyte
Resolution Biosciences
VolitionRx


CHAPTER 6: MULTI-ANALYTE LIQUID BIOPSY TESTS
INTRODUCTION
LIQUID BIOPSY TESTS BASED ON MULTIPLE ANALYTES
  • Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021


Biocept
Biodesix
Foundation Medicine (Roche)
LungLife AI
NeoGenomics
OncoDNA
MULTIPLE ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
  • Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2021


Exact Sciences
Freenome
GRAIL
LungLife AI


CHAPTER 7: LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY
INTRODUCTION
LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY
  • Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2021


Agena Bioscience
ANGLE
DiaCarta
Exosome Diagnostics
Guardant Health
Natera
QIAGEN


CHAPTER 8: LIQUID BIOPSY INDUSTRY ANALYSIS
INTRODUCTION
TIERS OF COMPETITION
  • Table 8-1: Selected Participants in the Liquid Biopsy Market, 2021


COMPETITIVE FACTORS
SIGNIFICANT MARKET TRENDS
  • Table 8-2: Significant Trends in the Liquid Biopsy Market, 2021


Personalized Medicine
Increasing Global Life Expectancy
New Liquid Biopsy Products
Increasing Accessibility of Genetic Testing
Regulatory Hurdles
Third-Party Payor Coverage
Demonstrated Clinical Utility
Incidence Rates of Specific Cancers
COMPETITORS NO LONGER IN THE LIQUID BIOPSY MARKET
  • Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market


CHAPTER 9: LIQUID BIOPSY MARKET
MARKET OVERVIEW
  • Figure 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Analyte, 2021 (%)
  • Figure 9-2: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2021 (%)
  • Figure 9-3: Global Liquid Biopsy Market Estimate by Type of Use, (Research Use, Clinical Diagnostics Use) 2018 (%)


MARKET FORECAST
  • Table 9-1: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World, World ($ millions), 2021-2026
  • Figure 9-4: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World ( $ millions), 2021-2026


CHAPTER 10: MARKET BY ANALYTE CIRCULATING TUMOR DNA
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
  • Table 10-1: Global Liquid Biopsy Market for ctDNA ($ millions), 2021-2026


CIRCULATING TUMOR CELLS
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
  • Table 10-2: Global Liquid Biopsy Market for CTCs ($ millions), 2021-2026


EXTRACELLULAR VESICLES AND OTHER ANALYTES
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
  • Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles ($ millions), 2021-2026


MULTIPLE ANALYTES
Market Overview
Revenue Forecast
  • Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2018-2023


CHAPTER 11: MARKET BY APPLICATION
THERAPY GUIDANCE AND MONITORING
Market Overview
Revenue Forecast
  • Table 11-1: Liquid Therapy for Therapy Guidance ($ millions), 2021-2026


DIAGNOSIS/SCREENING
Market Overview
Revenue Forecast
  • Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening ($ millions), 2021-2026


DISEASE PROGNOSIS
Market Overview
Revenue Forecast
  • Table 11-3: Global Liquid Biopsy Market for Disease Prognosis ($ millions), 2021-2026


CHAPTER 12: MARKET BY CANCER TYPE
BREAST CANCER
Market Overview
Revenue Forecast
  • Table 12-1: Global Liquid Biopsy Market for Breast Cancer ($ millions), 2021-2026


COLORECTAL CANCER
Market Overview
Revenue Forecast
  • Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer ($ millions), 2021-2026


LUNG CANCER
Market Overview
Revenue Forecast
  • Table 12-3: Global Liquid Biopsy Market for Lung Cancer ($ millions), 2021-2026


OVARIAN CANCER
Market Overview
Revenue Forecast
  • Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer ($ millions), 2021-2026


PROSTATE CANCER
Market Overview
Revenue Forecast
  • Table 12-5: Global Liquid Biopsy Market for Prostate Cancer ($ millions), 2021-2026


OTHER CANCERS
Market Overview
Revenue Forecast
  • Table 12-6: Global Liquid Biopsy Market for Other Cancers ($ millions), 2021-2026


Notes: *Including bladder, gastrointestinal, pancreatic, renal, melanoma and hematological malignancies.
PAN-CANCER TESTS
Market Overview
Revenue Forecast
  • Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing ($ millions), 2021-2026


CHAPTER 13: LIQUID BIOPSY COMPANY PROFILES
TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET
  • Table 13-1 Top Ten Companies in the Liquid Biopsy Market


ADAPTIVE BIOTECHNOLOGIES
AGENA BIOSCIENCE, INC.
ANGLE, PLC
ASPIRA WOMEN’S HEALTH
BIOCARTIS GROUP NV
BIOCEPT, INC.
BIODESIX
CELLMAX LIFE
CIRCULOGENE
DIACARTA, INC.
EPIC SCIENCES
EPIGENOMICS AG
EXACT SCIENCES
EXOSOME DIAGNOSTICS, INC.
FOUNDATION MEDICINE, INC. (ROCHE)
FREENOME, INC.
GILUPI GMBH
GRAIL (ILLUMINA)
GUARDANT HEALTH, INC.
HOLOGIC
LUNGLIFE AI (FORMERLY CYNVENIO BIOSYSTEMS)
MDXHEALTH
MENARINI-SILICON BIOSYSTEMS, SPA
MYRIAD GENETICS, INC.
NATERA, INC.
NEOGENOMICS LABORATORIES, INC.
ONCOCYTE CORPORATION
ONCODNA S.A.
ONCIMMUNE
PERSONAL GENOME DIAGNOSTICS
PREDICINEQ2 SOLUTIONSQIAGEN N.V.
Cell-free DNA Technologies
CTC Technologies
Exosome and miRNA Technologies
RESOLUTION BIOSCIENCES (AGILENT)
ROCHE DIAGNOSTICS
STAGEZERO LIFE SCIENCES
SYSMEX-INOSTICS, INC.
TEMPUS
VERACYTE
VOLITIONRX

Companies Mentioned

  • Adaptive Biotechnologies
  • Agena Bioscience, Inc.
  • Angle, plc
  • Aspira Women’S Health
  • Biocartis Group Nv
  • Biocept, Inc.
  • Biodesix
  • Cellmax Life
  • Circulogene
  • Diacarta, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Exact Sciences
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc. (Roche)
  • Freenome, Inc.
  • Gilupi GmbH
  • Grail (Illumina)
  • Guardant Health, Inc.
  • Hologic
  • Lunglife Ai (Formerly Cynvenio Biosystems)
  • Mdxhealth
  • Menarini-Silicon Biosystems, Spa
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Neogenomics Laboratories, Inc.
  • Oncocyte Corporation
  • Oncodna S.A.
  • Oncimmune
  • Personal Genome Diagnostics
  • Predicineq2 Solutionsqiagen N.V.
  • Cell-Free Dna Technologies
  • Ctc Technologies
  • Exosome and Mirna Technologies
  • Resolution Biosciences (Agilent)
  • Roche Diagnostics
  • Stagezero Life Sciences
  • Sysmex-Inostics, Inc.
  • Tempus
  • Veracyte
  • Volitionrx